Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2026-04-06 16:28:06 ET · period of report 2026-04-02 · accession 0002064832-26-000148 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-04-06 16:28 | 2026-04-02 | RNAC | Kalayoglu Murat | 10% | M - OptEx | — | +758.0K | 5.31M | +17% | — |
| DI | 2026-04-06 16:28 | 2026-04-02 | RNAC | Kalayoglu Murat | 10% | M - OptEx | — | -22.7K | 33.7K | -40% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-02 | M | A | 758,001 | — | 5,313,261 | I by trust | — | — | (F1) On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation. (F2) Shares are held by the Trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the Trust. |
| 2 | Derivative | Series A Non-Voting Convertible Preferred Stock | 2026-04-02 | M | D | 22,740.03 | — | 33,662.22 | I by trust | — · — to — | 758,001 Common Stock | (F1) On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation. (F3) On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the "Merger"). These securities represent merger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023. (F1) On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation. (F1) On April 2, 2026, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation. (F2) Shares are held by the Trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the Trust. |